Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Status:
RECRUITING
Trial end date:
2029-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.